CoChat

Targeted inhibition of the FGF 19‐FGFR 4 pathway in hepatocellular carcinoma; translational safety considerations

Open access
Mellor, Howard R. · 2014 · Liver International
Cited by 45

The DOI matches its Crossref record; 6 of the 6 references it cites were found in a registry or an index.

Abstract

Hepatocellular carcinoma (HCC) is a leading cause of cancer‐related death and new therapies are urgently required to treat this disease. Recent data suggest that the FGF 19‐FGFR 4 axis may be a key driver in certain forms of HCC, making the pathway an interesting, emerging molecular target for potential therapeutic intervention. A complication is that, outside of malignant disease, FGFR 4 plays an important physiological role in the regulation of hepatic bile acid (BA) synthesis. FGF 19 signalling via FGFR 4 suppresses de novo BA production in the liver, tightly maintaining hepatic and systemic levels of these detergent‐like molecules at a physiological threshold and preventing pathological complications of raised BA levels, such as cholestatic liver injury and bile acid diarrhoea. In some cases of HCC, the malignant disease causes bile duct obstruction, preventing BA secretion from the liver and resulting in cholestasis. Here, the role of FGFR 4 signalling in both HCC and BA homoeostasis is discussed. The potential effects of therapeutic FGF 19‐FGFR 4 inhibition on human hepatobiliary/gastrointestinal physiology are considered along with the potential safety implications of FGF 19‐FGFR 4 blockade in patients with HCC.

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1111/liv.12462

Cites

6 of 6 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 6 references

Cited by

See all 45

Metadata

Authors
Mellor, H. R.
Venue
Liver International
Publisher
Wiley
Published
2014-01-24
Volume
34
Issue
6
Pages
e1-9
ISSN
  • 0106-9543 (ISSN-L)
  • 1478-3223
  • 1478-3231
OpenAlex
W2026944977
Cited by
45
References
6
FWCI
2.43
Type
journal article
Language
en
Open access
bronze

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Targeted inhibition of the FGF 19‐FGFR 4 pathway in hepatocellular carcinoma; translational safety considerations. https://app.cochat.ai/papers/10.1111/liv.12462
The paper
Mellor, H. R. (2014). Targeted inhibition of the FGF 19‐FGFR 4 pathway in hepatocellular carcinoma; translational safety considerations. Liver International. https://doi.org/10.1111/liv.12462

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.